|Articles|February 1, 2011

Applied Clinical Trials-02-01-2011
Volume 20
Issue 2

Applied Clinical Trials Digital Edition - February 2011

INFORMATION TECHNOLOGY : A Risk-Based Approach for Computer Systems Validation SITES : Trial Monitoring - Source Document Verification REGULATORY : FDA's Guidance on Patient-Reported Outcomes ALSO IN THIS ISSUE : FDA's Oversight Capabilities Increased, Influenza Warning Issued, Cloud Computing: A Reality?, Guidance Says Focus on the Patient

External Link - article-821534.pdf

Articles in this issue

almost 16 years ago

Article

Applied Clinical Trials Digital Edition - February 2011, Supplement

almost 16 years ago

Article

Rates Increase Abroad Due to High Demand

almost 16 years ago

Article

Hispanics Remain Minority in Clinical Trials

almost 16 years ago

Article

State Cash Fuels Growth in England

almost 16 years ago

Article

Act Cover

almost 16 years ago

Article

almost 16 years ago

Article

The FDA's Guidance on PRO

almost 16 years ago

Article

H1N1 Influenza: Not to be Sneezed at

almost 16 years ago

Article

Cardiovascular Drug Trial Discontinued

almost 16 years ago

Article

New Approach to System Validation

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 12th, 2026

Why APAC Clinical Trial Sites Deserve a Second Look: Q&A with James Cheong, Precision for Medicine

In this Q&A, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, discusses why outdated perceptions of APAC sites persist among smaller biotechs, how China’s regulatory reforms have reshaped Phase III startup timelines, and what first-time sponsors need to get right in the region.

November 12th, 2026

ACT Brief: APAC Sponsor Priorities, Continuous Glucose Monitoring Trials, and GLP-1 Eye Warning

In today’s ACT Brief, we examine three priorities for first-time APAC sponsors, how continuous glucose monitoring should be used in diabetes trials, and why FDA is requiring a new eye-related warning across GLP-1 medications.

November 11th, 2026

What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, shares three priorities for first-time APAC sponsors: aligning with marketing authorization plans, selecting the right sites, and choosing a CRO with regional experience and KOL networks.

How regulatory guidance, blinding, study-provisioned devices, and ePRO integration shape reliable CGM data collection in diabetes clinical trials. Credit: Stock.Adobe.com/martenaba

November 11th, 2026

Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices

FDA and EMA expectations shape how sponsors use CGM in diabetes trials, from blinding and study-provisioned devices to data integrity and ePRO integration.

November 11th, 2026

ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval

In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.

November 10th, 2026

The Role of Clinical Research Professionals: From Early Discovery to Phase III Success

A pivotal trial that missed its primary endpoint became the basis for a successful redesign after the team used the data to define the high-risk patients most likely to benefit, showing that setbacks can strengthen development when organizations interrogate the evidence rather than abandon it.

November 10th, 2026

What Large Pharma Has Figured Out About APAC That Smaller Biotechs Are Still Learning

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, outlines why faster recruitment, local data requirements for registration, and lower costs make APAC attractive for global Phase III programs.

November 10th, 2026

ACT Brief: China’s Startup Timelines, AI-Drafted Clinical Study Reports, and Bimzelx Psoriatic Arthritis Data

In today’s ACT Brief, we examine how China’s trial startup timelines compare with those in the US and Europe, whether AI-drafted clinical study reports speed drug development, and how Bimzelx compared with Skyrizi in psoriatic arthritis.